GLP-1 receptor agonists may not increase the risk of acute kidney injury for cancer patients, new research suggests.

ASN Kidney Week 2024
Go to source). This finding clarifies earlier concerns about AKI risks associated with GLP-1RA usage in these patients. For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over 1 year.
‘ Did You Know?
Acute kidney injury affects up to 20% of hospitalized patients worldwide. #diabetes #acutekidneyinjury ’

Acute kidney injury affects up to 20% of hospitalized patients worldwide. #diabetes #acutekidneyinjury ’





Reassuring Findings for Cancer Patients
Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.“Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during the administration of anti-cancer therapy,” said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health.
“We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.”
Reference:
- ASN Kidney Week 2024 - (https://www.asn-online.org/education/kidneyweek/)
Source-Eurekalert